Newsletter
NEWS AND EVENTS
Home
Company
PIPELINE AND PORTFOLIO
Investor Relations
News and Events
Contact
Privacy Policy
Disclaimer
Imprint
Archive Press
© relief therapeutics 2025
Latest News
Stay up to date on Relief activities
Corporate News
Archive
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08 October 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Publishes 2025 Half-Year Report
14 August 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11 August 2025 | non-Ad Hoc
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29 July 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20 June 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Results of Annual General Meeting
12 June 2025 | non-Ad Hoc
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22 May 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15 May 2025 | non-Ad Hoc
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10 April 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06 March 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11 February 2025 | non-Ad Hoc
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
22 January 2025 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
27 December 2024 | non-Ad Hoc
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
16 December 2024 | non-Ad Hoc
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
13 December 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
04 November 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29 October 2024 | non-Ad Hoc
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21 October 2024 | Ad Hoc Announcement pursuant to Art. 53 LR
Company
Pipeline
Investor Relations
News and Events
© Relief Therapeutics